MedTrace Logo

Peri-operative Aspirin Continuation Versus Discontinuation

NCT02350543 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-04-08

No results posted yet for this study

Summary

This study evaluates the continuation (non-discontinuation) of Aspirin during TURBT. Half of participants will continue their usual low-dose Aspirin regimen during TURBT and throughout the perioperative period, while the other half will discontinue Aspirin use ten days prior to surgery (standard recommendation) and restart therapy two weeks post-discharge.

Conditions

  • Hematuria
  • Urinary Bladder Neoplasms

Interventions

DRUG

Aspirin

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Marc A Lubin, MD · Department of Urology, Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02350543 on ClinicalTrials.gov